Somewhat Positive Media Coverage Somewhat Unlikely to Impact Neuralstem (CUR) Stock Price
Headlines about Neuralstem (NASDAQ:CUR) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neuralstem earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.1327525402976 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern’s rankings:
- Contrasting Neuralstem (CUR) and The Competition (americanbankingnews.com)
- Neuralstem (CUR) Reports Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at at ACNP Meeting (streetinsider.com)
- Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting (finance.yahoo.com)
- Neuralstem, Inc. (NASDAQ:CUR) Files An 8-K Results of Operations and Financial Condition (4-traders.com)
- Comparing Sophiris Bio (SPHS) & Neuralstem (CUR) (americanbankingnews.com)
Shares of Neuralstem (NASDAQ CUR) opened at $1.12 on Tuesday. Neuralstem has a 1 year low of $0.88 and a 1 year high of $6.60.
Separately, ValuEngine downgraded shares of Neuralstem from a “hold” rating to a “sell” rating in a research report on Tuesday, July 25th.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Neuralstem (CUR) Stock Price” was first posted by Daily Political and is owned by of Daily Political. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/11/21/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-neuralstem-cur-stock-price.html.
Neuralstem Company Profile
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.